(Q36054877)

11 August 2017

1 reference

title

Novel therapies in lupus nephritis (English)

1 reference

11 August 2017

2

D A Isenberg

1 reference

11 August 2017

H Tahir

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

77-82

1 reference

Cyclophosphamide for the treatment of systemic lupus erythematosus

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

B cell depletion therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Monoclonal antibodies and other biologic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

A therapeutic role for BLyS antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Autologous stem cell transplantation for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2064OA

10.1191/0961203305LU2064OA

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference